Navigation Links
ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones

FREDERICK, Md., April 1, 2008 /PRNewswire/ -- ImQuest BioSciences, Inc. announced today the publication of the results of an important structure- activity relationship study to investigate the efficacy and toxicity of a series of pyrimidinedione analogs against HIV-1 and HIV-2. The manuscript, published in the journal Antiviral Chemistry and Chemotherapy, shows the results of ImQuest's HIV drug development program based on compounds which it licensed from Samjin Pharmaceutical Co. Ltd. The report, authored by Robert W. Buckheit, Jr., Ph.D. (Executive Vice President and Chief Scientific Officer of ImQuest) describes the synthesis of the highly potent pyrimidinedione series and the structural features of the compounds which are responsible for their high level of potency against HIV, the expanded range of action to include HIV-2, and the unique dual mechanism of entry and RT inhibitory activity against HIV-1.

"The studies performed will allow us to focus our resources on the preclinical and clinical development of the most potent lead pyrimidinedione and to gain insight into the molecular features of the compounds which yield the high potency and characteristic dual mechanism of antiviral action of these unique compounds," explained Dr. Buckheit. Other coauthors on this paper include ImQuest virologists Tracy Hartman, Karen Watson and Lu Yang and Samjin chemists Ho-Seok Kwon, Sun-Hwan Lee, Jae-Woong Lee, Dong-Wook Kang, Sun-Gan Chung and Eui-Hwan Cho.

ImQuest expects to submit an IND to initiate Phase 1 human clinical trials with IQP-0410, a highly potent member of the pyrimidinedione series in the third quarter of 2008. In addition, ImQuest has initiated IND-enabling studies with the pyrimidinedione IQP-0528 as a potential anti-HIV topical microbicide.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in early stage drug development of novel compounds for the treatment of infectious disease and cancer. Samjin Pharmaceutical Co., a publicly held company listed on the Korean Stock Exchange, is one of the leading pharmaceutical companies in Korea. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti- cancer drug and vaccine development services to the biotechnology and pharmaceutical industry.

For further information regarding this press release please contact:

Robert W. Buckheit, Jr., Ph.D.

Executive Vice President and Chief Scientific Officer

ImQuest Life Sciences, Inc.


SOURCE ImQuest BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
5. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
6. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
(Date:11/26/2015)... 26, 2015 --> ... SyMRI to find optimal contrast weighting of MRI for ... has signed a research agreement with SyntheticMR in order to ... SyMRI, it is possible to generate multiple contrast images from ... patient has left, thus making it possible to both fine ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
Breaking Medicine Technology:
(Date:11/26/2015)... NV (PRWEB) , ... November 26, 2015 , ... Inevitably ... strategy. Many customers choose to buy during the Black Friday and Cyber Monday ... Shoppers don’t need to search the Internet high and low to find the best ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating ... our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment ... day excited to rebuild lives and it’s an honor to have served all of ...
(Date:11/25/2015)... ... 25, 2015 , ... Additional breast cancers found with MRI ... to a study published online in the journal Radiology. Researchers said that in ... a change in treatment. , Breast MRI is the most sensitive technique for ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... factory direct sauna parts and accessories. , Sauna accessories help improve the bather ... style and personality. From basic styles for the purist looking for simplicity in ...
(Date:11/25/2015)... Los Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... advanced da Vinci surgical robot is being more and more widely heralded as a ... robotic assisted da Vinci method has over traditional laparoscopic surgery is that it can ...
Breaking Medicine News(10 mins):